EGFR and diabetic kidney disease: This suggests that inhibiting EGFR activation may be beneficial, not only in preventing sodium and water retention generally observed in patients with diabetic nephropathy, but also in limiting sodium and water retention associated with the use of PPARγ agonists in patients with diabetes mellitus.